Financial Statements

Sorrento Therapeutics, Inc. (SRNE)

$0.3073

0.00 (0.00%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands , Years are calendar years not fiscal years

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) -1,387-958-660-368-
Net Income -559-429-309-359-204
Stock Dividends -1411067-164
Dividend Paid -----
Retained Earnings -1,959-1,387-958-660-368

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 126747624-
Annual Depreciation 2661356336
Capital Expenditure -14-9-38-11-11
Net PPE 138126747624

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -38384480
New Purchases -----
Intangible and Goodwill 3838448080

Sorrento Therapeutics, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Sorrento Therapeutics, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.